Antidepressants for the new millennium

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 31-40

  Skolnick, Phil ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Brain derived neurotrophic factor; Monoamine; Neurotrophin; NMDA receptor

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; DESIPRAMINE; DIZOCILPINE; IFENPRODIL; IMIPRAMINE; KETAMINE; MEMANTINE; MESSENGER RNA; METAPRAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTROPHIN; PAPAVERINE; PSYCHEDELIC AGENT; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

LIGAND BINDING; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; BRAIN; CLINICAL TRIALS; FORECASTING; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES;

EID: 0032983086     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00330-1     Document Type: Review

References (72)

1. Altar C.A. Neurotrophins and depression. Trends Pharmacol. Sci. 20:1999;59-61.
2. Armstrong R.C., Montminy M.R. Transsynaptic control of gene expression. Annu. Rev. Neurosci. 16:1993;17-29.
3. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
4. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15730-15734.
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry. 154:1997;37-43.
6. Boireau A., Bordier F., Durand G., Doble A. The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors. Neuropharmacology. 12:1996;1703-1707.
7. Borsini F., Meli A. Is the forced swim test a suitable model for revealing antidepressant activity? Psychopharmacology. 94:1988;147-160.
8. Boyer P.-A., Skolnick P., Fossom L.H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. J. Mol. Neurosci. 10:1998;219-233.
9. Brandoli C., Sanna A., De Bernardi M.A., Follesa P., Brooker G., Mocchetti I. Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. J. Neurosci. 18:1998;7953-7961.
10. Cappiello, A., Berman, R.M., Anand, A., Charney, D.S., Krystal, J.H., 1998. NMDA receptor function in major depression. The Glutamate Cascade: Common Pathways of Central Nervous System Diseases. p. 44 (abstract).
11. Cherkofsky S.C. 1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. J. Pharm. Sci. 84:1995;1231-1235.
12. Choi D. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
13. 2+ in dissociated brain cells. Brain Res. 499:1989;383-387.
14. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry. 54:1997;597-606.
15. Duman, R.S., Nibuya, M., Vaidya, V.A., 1997. A role for CREB in antidepressant action. In: Skolnick, P. (Ed.), Antidepressants: New Pharmacological Strategies. Humana Press, Totowa, pp. 173-194.
16. Evoniuk G.E., Hertzman R.P., Skolnick P. A rapid method for evaluating the behavioral effects of dissociative anesthetics in mice. Psychopharmacology. 105:1991;125-128.
17. Hayashi T., Umemori H., Mishina M., Yamamoto T. The AMPA receptor interactions with and signals through the protein tyrosine kinase Lyn. Nature. 397:1999;72-76.
18. He Y., Janssen W.G.M., Morrison J.H. Synaptic coexistence of AMPA and NMDA receptors in the rat hippocampus: a postembedding immunogold study. J. Neurosci. Res. 54:1998;444-449.
19. Horowski R., Sastre, Hernandez M. Clinical effects of the neurotrophic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr. Ther. Res. 38:1985;23-29.
20. Huang, N.-Y., Layer, R.T., Skolnick, P., 1997. Is an adaptation of NMDA receptors an obligatory step in antidepressant action? In: Skolnick, P. (Ed.), Antidepressants: New Pharmacological Strategies. Humana Press, Totowa, pp. 125-143.
21. Huang N.-Y., Strakhova M., Layer R.T., Skolnick P. Chronic antidepressant treatments increase Cytochrome b mRNA levels in mouse cerebral cortex. J. Mol. Neurosci. 9:1997;167-176.
22. Hughes B., Owens R., Perry M., Warrellow G., Allen R. PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs. Drug Discovery Today. 2:1997;89-101.
23. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
24. Kew J.N.C., Trube G., Kemp J.A. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in cultured cortical neurones. J. Physiol. 497:1996;761-772.
25. Kornhuber J., Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry. 41:1997;135-144.
26. Kraus J.E., Nadler V.J., McNamara J.O. Regulation of alternative splicing of NMDAR1 in the kindling model. Mol. Brain Res. 41:1996;97-104.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremmer J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic doses of the noncompetitive NMDA antagonist, ketamine in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
28. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345.
29. Layer R.T., Popik P., Olds T., Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL 82.0715). Pharmacol. Biochem. Behav. 52:1995;621-627.
30. Layer, R.T., Popik, P., Nowak, G., Paul, I.A., Trullas, R., Skolnick, P., 1998. A unified theory of antidepressant action: evidence for adaptation of the N-methyl-D-aspartate (NMDA) receptor following chronic antidepressant treatments. In: Ceña, V., Soria, B. (Eds.), Ion Channel Pharmacology. Oxford University Press, Oxford, pp. 438-456.
31. Liang P., Pardee A.B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 257:1992;967-971.
32. Long J.B., Skolnick P. 1-Aminocyclopropanecarboxylic acid protects against dynorphin A-induced spinal injury. Eur. J. Pharmacol. 261:1994;295-301.
33. Loscher W., Annies R., Honack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions. Neurosci. Lett. 128:1991;191-194.
34. Maj J., Rogóz Z., Skuza G., Sowinska H. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol. J. Pharmacol. 44:1992;337-346.
35. Maj J., Rogóz Z., Skuza G., Sowinska H. The effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Neuropsychopharmacology. 2:1992;37-41.
36. Malison R.T., Price L.H., Nestler E.J., Heninger G.R., Duman R.S. Efficacy of papaverine addition for treatment-refractory major depression. Am. J. Psychiatry. 154:1997;579-580.
37. Mamounas L.A., Blue M.E., Sluciak J.A., Altar C.A. BDNF promotes the survival and sprouting of serotonergic axons in the rat brain. J. Neurosci. 15:1995;1729-1739.
38. Meshul C.K., Bunker G.L., Mason J.L., Allen C., Janowsky A. Effects of subchronic clozapine and haloperidol on strial glutamatergic synapses. J. Neurochem. 67:1996;1965-1973.
39. Montminy M.R., Gonzalez G.A., Yamamoto K.K. Regulation of cyclic AMP inducible genes by CREB. T.I.N.S. 13:1990;184-188.
40. Moryl E., Danysz W., Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 72:1993;394-397.
41. Naylor P., Steward C.A., Wright S.R., Pearson R.C.A., Reid J.C. Repeated electroconvulsive shock induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Mol. Brain Res. 35:1996;349-353.
42. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA following chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15:1995;7539-7547.
43. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16:1996;2365-2372.
44. Nowak G., Trullas R., Layer R.T., Skolnick P., Paul I.A. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J. Pharmacol. Exp. Ther. 265:1993;1380-1386.
45. Nowak G., Li Y., Paul I.A. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur. J. Pharmacol. 295:1996;75-85.
46. Ohayon M.M., Priest R.G., Guilleminault C., Caulet M. The prevalence of depressive disorders in the United Kingdom. Biol. Psychiatry. 45:1999;300-307.
47. Papp M., Moryl E. Similar effects of chronic treatment with imipramine and the NMDA antagonists CGP 37849 and MK-801 in a chronic mild stress model of depression in rats. Eur. J. Neuropsychopharmacol. 3:1993;348-349.
48. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263:1994;1-7.
49. Papp M., Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur. J. Pharmacol. 316:1996;145-151.
50. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated NMDA receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;85-108.
51. Patat A., Molinier P., Hergueta T., Brohier S., Zieleniuk I., Danjou Ph., Warot D., Puech A. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist. Int. Clin. Psychopharmacol. 9:1994;155-162.
52. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269:1994;95-102.
53. Porsolt, R.D., Lenegre, A., 1992. Behavioural models of depression. In: Elliott, J.M., Heal, D.J., Marsden, C.A. (Eds.), Experimental Approaches to Anxiety and Depression. Wiley, London, pp. 73-85.
54. Przegalinski E., Tartarczynska E., Deren-Wesolek A., Chojnacka-Wojcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA antagonist. Neuropharmacology. 36:1997;31-37.
55. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
56. Romano, C., Williams, K., 1994. Modulation of NMDA receptors by polyamines. In: Carter, C. (Ed.), The Neuropharmacology of Polyamines. Academic Press, London, pp. 81-106.
57. Rossby S.P., Nalepa I., Huang M., Perrin C., Burt A.M., Schmidt D.E., Gillespie D.D., Sulser F. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res. 687:1995;79-82.
58. Rossby, S.P., Sulser, F., 1997. Antidepressants: beyond the synapse. In: Skolnick, P. (Ed.), Antidepressants: New Pharmacological Strategies. Humana Press, Totowa, pp. 195-212.
59. Scatton, B., Avenet, P., Benavides, J., Carter, C., Duverger, D., Oblin, A., Perrault, G., Sanger, D., Schoemaker, H., 1994. Neuroprotective potential of the polyamine site-directed NMDA receptor antagonists - ifenprodil and eliprodil. In: Palfreyman, M.G., Reynolds, I.J., Skolnick, P. (Eds.), Direct and Allosteric Control of Glutamate Receptors. CRC Press, Boca Raton, pp. 139-154.
60. Skolnick P., Miller R., Young A., Boje K., Trullas R. Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology. 107:1992;489-496.
61. Suda S., Nibuya M., Ishiguro T., Suda H. Transcriptional and translational regulation of phosphodiesterase Type IV isozymes in rat brain by electroconvulsive and antidepressant drug treatment. J. Neurochem. 71:1998;1554-1563.
62. Sveinbjornsdottir S., Sander J.W.A.S., Upton D., Thompson P.J., Patsalos P.N., Hirt D., Emre M., Lowe D., Duncan J.S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16:1993;165-174.
63. Tong L., Perez-Polo R. Brain-derived neurotrophic factor (BDNF) protects cultured rat cerebellar granule neurons against glucose deprivation-induced apoptosis. J. Neural Transm. 105:1998;905-914.
64. Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8:1996;205-215.
65. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185:1990;1-10.
66. Trullas R., Folio T., Young A., Miller R., Boje K., Skolnick P. 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 203:1991;379-385.
67. Wafford K.A., Bain C.J., Le Bourdelles B., Whiting P.J., Kemp J.A. Preferential co-assembly of recombinant NMDA receptors composed of three different subunits. NeuroReport. 4:1993;1347-1349.
68. Wedzony K., Mackowiak M., Czyrak A., Fijal K., Michalska B. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res. 756:1997;84-91.
69. Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44:1993;851-859.
70. Willner P.A. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology. 134:1997;319-329.
71. Willner, P., Papp, M., 1997. Animal models to detect antidepressants: are new strategies necessary to detect new agents? In: Skolnick, P. (Ed.), Antidepressants: New Pharmacological Strategies. Humana Press, Totowa, pp. 213-234.
72. Zapata A., Capedivila J.L., Viu E., Trullas R. 1-Aminocyclopropanecarboxylic acid reduces NMDA-induced hippocampal neurodegeneration in vivo. NeuroReport. 7:1996;397-400.